Most novel influenza A (H1N1) 2009 infections presented mild respiratory disease. Prompt antiviral therapy in patients with A (H1N1) virus infection seem to be the best approach to avoid serious form of the disease. Special attention should be payed to patients having low level of peripheral oxygen saturation and raised CRP serum level.

The aim of this study was to investigate the differences of Clostridioides difficile infection (CDI) during the COVID-19 pandemic compared to the pre-COVID-19 era. CDI patients treated at the Clinic for Infectious Diseases, Clinical Center of Vojvodina, Serbia during 2017–2019 (n = 304) were compared with COVID-19/CDI patients treated in period September 2021–September 2022 (n = 387). Groups were compared by age, gender, comorbidities, previous medications, laboratory findings, and outcome within 30 days. In the CDI/COVID-19 group, we found: greater percentage of males 59.8% vs. 42.6% (p ≤ 0.001), older age 72.8 ± 9.4 vs. 65.6 ± 11.7 (p ≤ 0.001), higher Charlson comorbidity score (CCS) (3.06 ± 1.54 vs. 2.33 ± 1.34 (p ≤ 0.001), greater percentage of chronic renal failure (33.9% vs. 23.4% (p = 0.003), malignances (24.3% vs. 13.5% (p ≤ 0.001), chronic obstructive pulmonary disease (22.7% vs. 15.5% (p = 0.017), higher usage of macrolide (38.5% vs. 8.6% (p ≤ 0.001), greater percentage of patients with hypoalbuminemia ≤25 g/L (19.6% vs. 12.2% (p ≤ 0.001), lower percentage of patients with elevated creatinine (≥200 mmol/L) (31.5% vs. 43.8%) (p = 0.002), and greater percentage of lethal outcome 29.5% vs. 6.6% (p ≤ 0.001). In the prediction of lethal outcome multivariate regression analysis extracted as an independent predictor, only higher CRP values in the non-COVID-19 group and in the COVID-19 group: older age (p ≤ 0.001), CCS (p = 0.019) and CRP (p = 0.015). COVID-19 changes the disease course of CDI and should be taken into consideration when managing those patients.

We still don't have a special treatment for these kinds of infections. Variety of antiviral drugs with controversial effects have been reported in management of adenoviral infections in immunocompromised persons. In USA adenoviral vaccine has been excluded from vaccine schedules among military personnel, but morbidity and the first two deaths due to these infections in the last 30 years reported by MMWR in 2000, may change this policy.

Sažetak Uvod. Hronična hepatitis C virusna infekcija u starijem životnom dobu nije mnogo proučavana iako se očekuje porast prevalencije ove bolesti u starijoj populaciji. Materijal i metode. U radu su prikazane kliničko-epidemiološke karakteristike hroničnog hepatitisa kod 153 bolesnika starosti 65 i više godina, lečenih na Klinici za infektivne bolesti Kliničkog centra Vojvodine u Novom Sadu. Rezultati. Nešto zastupljenije su bile osobe ženskog pola − 55,55%; hepatitis C virusna infekcija je najčešće otkrivena slučajno, prilikom drugih pregleda, i najčešće je stečena postransfuziono-u 42,48% slučajeva. Prosečna dužina trajanja infekcije bila je 28,48 godina; ubedljivo najčešće je bila izazvana genotipom 1 hepatitis C virusa i patohistološkim pregledom biopsije jetre se najčešće radilo o teškoj fibrozi i cirozi − 72,22% slučajeva. Uspeh antivirusne terapije primenjene kod 16 bolesnika iznosio je 62,5%. Zaključak. Antivirusna terapija se kod osoba starijeg životnog doba retko primenjuje, ali uspeh od 62,5% u našem uzorku ukazuje na opravdanu primenu terapije uprkos starosti i komorbiditetima.